Literature DB >> 29713826

Pathologic significance of AKT, mTOR, and GSK3β proteins in oral squamous cell carcinoma-affected patients.

Flávia Sayuri Matsuo1, Marília Ferreira Andrade2, Adriano Mota Loyola3, Sindeval José da Silva4, Marcelo José Barbosa Silva2, Sérgio Vitorino Cardoso3, Paulo Rogério de Faria5,6.   

Abstract

Phosphatidylinositol-3-kinases are kinases that lead to AKT phosphorylation and thus mTOR and GSK3β activation. These proteins are linked to tumorigenesis, but their roles in driving cervical lymph node (CLN) metastasis of oral squamous cell carcinoma (OSCC) cells are unknown. This study aimed to investigate the role of AKT, mTOR, and GSK3β proteins in the occurrence of CLN metastasis in OSCC patients. Ninety and 18 paraffin-embedded OSCC and oral mucosa samples were included, respectively. We divided our OSCC patients into non-metastasizing (PNM) and metastasizing (PM) groups, and the expression of total AKT, pAKT1Thr308, pAKTSer473, GSK3β, pGSK3βSer9, and pmTORSer2448 was analyzed by immunohistochemistry. The mean expression of GSK3β, pGSK3βSer9, total AKT, and pmTOR2448 was always higher in the OSCC tissues than that in the controls. A positive correlation was also found among these proteins. Total AKT, pmTORSer2448, and pGSK3βSer9 expression was significantly higher in the PNM and PM groups than that in the control group. However, only GSK3β expression was significantly higher in the PM group compared with the PNM group. High expression levels of GSK3β and pGSK3βSer9 were significantly associated with CLN metastasis, but only GSK3β remained an independent predictor of CLN metastasis. pGSK3βSer9 and CLN metastasis were associated with a poor prognosis, but only the latter remained an independent prognostic parameter. Kaplan-Meier survival curves showed that pGSK3βSer9 and CLN metastasis were significantly related to reduced survival rates. These results suggest that AKT and mTOR proteins are involved in OSCC biology and that GSK3β itself may drive CLN metastatic spread of OSCC cells.

Entities:  

Keywords:  AKT; Cervical lymph node metastasis; Glycogen synthase kinase-3β, prognosis; Oral squamous cell carcinoma; mTOR

Mesh:

Substances:

Year:  2018        PMID: 29713826     DOI: 10.1007/s00428-018-2318-0

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  41 in total

1.  Involvement of inactive GSK3beta overexpression in tumorigenesis and progression of gastric carcinomas.

Authors:  Hua-chuan Zheng; Xiao-yan Xu; Pu Xia; Miao Yu; Hiroyuki Takahashi; Yasuo Takano
Journal:  Hum Pathol       Date:  2010-05-05       Impact factor: 3.466

2.  Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis.

Authors:  Marganit Farago; Isabel Dominguez; Esther Landesman-Bollag; Xin Xu; Andrea Rosner; Robert D Cardiff; David C Seldin
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

3.  Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.

Authors:  Matthew L Hedberg; Gerald Goh; Simion I Chiosea; Julie E Bauman; Maria L Freilino; Yan Zeng; Lin Wang; Brenda B Diergaarde; William E Gooding; Vivian W Y Lui; Roy S Herbst; Richard P Lifton; Jennifer R Grandis
Journal:  J Clin Invest       Date:  2016-04-01       Impact factor: 14.808

Review 4.  PI3K-Akt pathway: its functions and alterations in human cancer.

Authors:  M Osaki; M Oshimura; H Ito
Journal:  Apoptosis       Date:  2004-11       Impact factor: 4.677

Review 5.  The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies.

Authors:  R Vander Broek; S Mohan; D F Eytan; Z Chen; C Van Waes
Journal:  Oral Dis       Date:  2013-12-23       Impact factor: 3.511

6.  PIK3CA mutations in head and neck squamous cell carcinoma.

Authors:  Wanglong Qiu; Frank Schönleben; Xiaojun Li; Daniel J Ho; Lanny G Close; Spiros Manolidis; Boyce P Bennett; Gloria H Su
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

Review 7.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations.

Authors:  Jeffrey A Engelman
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

8.  Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth.

Authors:  Hugo A Acosta-Jaquez; Jennifer A Keller; Kathryn G Foster; Bilgen Ekim; Ghada A Soliman; Edward P Feener; Bryan A Ballif; Diane C Fingar
Journal:  Mol Cell Biol       Date:  2009-06-01       Impact factor: 4.272

9.  Tissue microarrays for high-throughput molecular profiling of tumor specimens.

Authors:  J Kononen; L Bubendorf; A Kallioniemi; M Bärlund; P Schraml; S Leighton; J Torhorst; M J Mihatsch; G Sauter; O P Kallioniemi
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440

10.  Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.

Authors:  Irina Fenic; Klaus Steger; Christin Gruber; Christoph Arens; Joachim Woenckhaus
Journal:  Oncol Rep       Date:  2007-07       Impact factor: 3.906

View more
  13 in total

1.  Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses.

Authors:  Ilyas Sahin; Aditya Eturi; Andre De Souza; Sahithi Pamarthy; Fabio Tavora; Francis J Giles; Benedito A Carneiro
Journal:  Cancer Biol Ther       Date:  2019-04-12       Impact factor: 4.742

2.  Molecular biology of oral cavity squamous cell carcinoma.

Authors:  Phillip J Hsu; Kenneth Yan; Hailing Shi; Evgeny Izumchenko; Nishant Agrawal
Journal:  Oral Oncol       Date:  2020-01-07       Impact factor: 5.337

Review 3.  Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer.

Authors:  Michelle J Lee; Nan Jin; Jennifer R Grandis; Daniel E Johnson
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2020-02-19       Impact factor: 4.739

Review 4.  Genetic alterations and clinical dimensions of oral cancer: a review.

Authors:  Keerthana Karunakaran; Rajiniraja Muniyan
Journal:  Mol Biol Rep       Date:  2020-10-21       Impact factor: 2.316

Review 5.  Targeting AKT/mTOR in Oral Cancer: Mechanisms and Advances in Clinical Trials.

Authors:  Choudhary Harsha; Kishore Banik; Hui Li Ang; Sosmitha Girisa; Rajesh Vikkurthi; Dey Parama; Varsha Rana; Bano Shabnam; Elina Khatoon; Alan Prem Kumar; Ajaikumar B Kunnumakkara
Journal:  Int J Mol Sci       Date:  2020-05-06       Impact factor: 5.923

6.  Glycogen Synthase Kinase-3 Beta Expression Correlates With Worse Overall Survival in Non-Small Cell Lung Cancer-A Clinicopathological Series.

Authors:  Marclesson Alves; Daniela de Paula Borges; Aline Kimberly; Francisco Martins Neto; Ana Claudia Oliveira; Juliana Cordeiro de Sousa; Cleto D Nogueira; Benedito A Carneiro; Fabio Tavora
Journal:  Front Oncol       Date:  2021-03-09       Impact factor: 6.244

Review 7.  PI3K/AKT Signal Pathway: A Target of Natural Products in the Prevention and Treatment of Alzheimer's Disease and Parkinson's Disease.

Authors:  Hui-Zhi Long; Yan Cheng; Zi-Wei Zhou; Hong-Yu Luo; Dan-Dan Wen; Li-Chen Gao
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

Review 8.  Autophagy-A Hidden but Important Actor on Oral Cancer Scene.

Authors:  Totan Alexandra; Imre Melescanu Marina; Miricescu Daniela; Stanescu Iulia Ioana; BencZe Maria; Radulescu Radu; Tancu Ana Maria; Spinu Tudor; Greabu Maria
Journal:  Int J Mol Sci       Date:  2020-12-07       Impact factor: 5.923

9.  Anticancer effects of 6-shogaol via the AKT signaling pathway in oral squamous cell carcinoma.

Authors:  Hai Huang; Myoung-Ok Kim; Ki-Rim Kim
Journal:  J Appl Oral Sci       Date:  2021-10-11       Impact factor: 2.698

10.  Assessment of PI3K/mTOR/AKT Pathway Elements to Serve as Biomarkers and Therapeutic Targets in Penile Cancer.

Authors:  Anita Thomas; Sascha Reetz; Philipp Stenzel; Katrin Tagscherer; Wilfried Roth; Mario Schindeldecker; Martin Michaelis; Florian Rothweiler; Jindrich Cinatl; Jaroslav Cinatl; Robert Dotzauer; Olesya Vakhrusheva; Maarten Albersen; Stephan Macher-Goeppinger; Axel Haferkamp; Eva Juengel; Andreas Neisius; Igor Tsaur
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.